Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

NCT02689219 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

18

Enrollment

OTHER

Sponsor class

Stopped lack of funding/ benefit

Conditions

Germ Cell Tumors
Testis Cancer
Testicular Cancer
Embryonal Carcinoma
Nonseminomatous Germ Cell Tumor

Interventions

DRUG: Brentuximab Vedotin

Sponsor

Nabil Adra